Purethal
Phase 3Small molecule
Purethal is one of 28 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Sudafed
KKenvue Brands
Phase 3
Asmanex HFA
Sumitomo Pharma America, Inc.Phase 3
Ciclesonide HFA
Sumitomo Pharma America, Inc.Phase 3
EMS Acarbose
EEMS
Phase 3
Asmanex
NovartisPreclinical
HL151
HHanlim Pharm. Co., Ltd.
Phase 3
Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
Purethal
MMedical University of Silesia
Phase 3
Xolair
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Purethal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMedical University of Silesia